Novo Nordisk's pricing approaches inside the U.S. have drawn sharp criticism from lawmakers like Senator Sanders, who has accused the company of value gouging, declaring the stark contrast involving U.S. selling prices and those in Europe and copyright. Incorporate these bits and items in